Please select the eligibility criteria that correspond to the clinical trial below.
Title: Normal Voiding Function After Surgical Repair of Pelvic Organ Prolapse: A Randomized Trial Comparing Day of Surgery Retrograde Void Trials to Standard Postoperative Day One Retrograde Void Trials
Brief Summary: The primary aim of this study is to determine if normal bladder function (the ability to empty the bladder during spontaneous urination) after surgical repair of pelvic organ prolapse returns faster in patients who have a retrograde voiding trial the day of surgery versus patients who have a retrograde voiding trial on postoperative day one. Half of participants will have a voiding trial 4 hours after surgery, while the other half will have the voiding trial postoperative day one.


Options:
A: Inclusion Criteria:

* surgical management of pelvic organ prolapse requiring an overnight hospital admission

Exclusion Criteria:

* same day surgery
* non-ambulatory (allowed to use an assistive device)
* inability to provide informed consent, age \< 21 years
* pregnancy or desire for future pregnancy
* systematic disease known to affect bladder function (Parkinson's disease, Multiple Sclerosis, Spina Bifida, spinal cord injury or trauma and neurogenic bladder)
* known preoperative urinary retention (defined as a post-void residual \> 100mL)
* an untreated urinary tract infection at the time of surgery
* treatment at the time of surgery for urinary tract infection
* symptoms of urinary tract infection on the day of surgery
B: Inclusion Criteria:

* Patients between 20-80 years old in general good health
* Patient willing to participate in the study
* Patient who understands and accepts to sign the informed consent form
* Patient who received proctectomy for rectal cancer located 15 cm or less of the anal verge

Exclusion Criteria:

* Documented problem of preoperative urinary dysfunction
* Any post-surgery change in patient condition which requires insertion of urinary catheter after surgery
* Past history of recurrent urinary tract infection or malignancy of urinary system organs
* Past history of surgery for urinary system organs
* Current administration of Finasteride or Dutasteride
* Liver dysfunction (SGOT or SGPT 100 IU/L or more)
* Kidney dysfunction (serum Creatinine 3mg/dl or more)
C: Inclusion Criteria:

1. Competent to consent to participate in trial
2. Patients with rectal cancer who underwent total or tumor-specific-mesorectal excision with colorectal or colonanal anastomosis
3. Elective surgery
4. ASA classification of 1\~3
5. If male, international prostate symptom score \<20.

Exclusion Criteria:

1. Combined pelvic surgery(pelvic lymph node dissection, hysterectomy, salpingo-oophorectomy, posterior vaginectomy, cystectomy, ureteral double-J stenting, ureterectomy, ureteroureterostomy, prostatectomy)
2. Postoperative complications with a Dindo grade III or more
3. Known urinary disease(end-stage renal disease, benign prostatic hyperplasia, neurogenic bladder, malignancy)
D: Inclusion Criteria:

* Uterine fibroids
* Endometriosis
* Abnormal bleeding
* Uterine prolapse and intra-epithelial neoplasia of the cervix grade 3

Exclusion Criteria:

* If they experienced pelvic reconstructive surgery for pelvic organ prolapse or stress urinary incontinence
* If they have bacteriuria and clinical urinary tract symptoms, e.g. dysuria, frequency, urgency and stress incontinence before surgery

Answer: A